Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: A meta-analysis of controlled trials

AIDS

Volumn 11, Issue 4, 1997, Pages 477-483

  Staszewski, Schlomo ^a   Hill, Andrew M ^b   Bartlett, John ^c   Eron, Joseph J ^d   Katlama, Christine ^e   Johnson, Judy ^b   Sawyer, William ^f   McDade, Hugh ^b  

^a GOETHE UNIVERSITY   (Germany)

^b GLAXOSMITHKLINE   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Antiviral therapy; Disease progression

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NORTH AMERICA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031058463     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199704000-00011     Document Type: Article

References (25)

1. Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
2. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-1 infected individuals with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
3. Gullick R, Mellors J, Havlir D, et al.: Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC). 3rd Conference on Retroviruses and Opportunistic Infection, Washington, DC, January 1996 [abstract LB-7].
4. 3. International on Drug Therapy in HIV infection. Birmingham, November 1996. [abstract OP4.1]
5. Mellors JW, Rinaldo CR, Gupta P, et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
6. Loveday C, Hill A: Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet 1995, 345:790-791.
7. O'Brien WA, Hartigan PM, Martin D, et al.: The relationship of treatment induced changes in plasma HIV-1 RNA and CD4+ lymphocyte count to progression to AIDS in The Department of Veteran Affairs Zidovudine Study. N Engl J Med 1996, 334:426-431.
8. Phillips AN, Eron JJ, Bartlett JA, et al.: HIV-1 RNA levels and the development of clinical disease. AIDS. 1996, 10:859-867
9. Katlama C, Ingrand D, Loveday C, et al.: Safety and efficacy of lamivudine/zidovudine combination therapy in antiretroviral naive patients. JAMA 1996, 276:118-125.
10. Staszewski S, Loveday C, Picazo J, et al.: Safety and efficacy of lamivudine-zidovudine combination in zidovudine experienced patients. JAMA 1996, 276:111-117.
11. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
12. Bartlett JA, Benoit SL, Johnson VA, et al.: Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. Ann Intern Med 1996, 125:161-172.
13. Centres for Disease Control and Prevention: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1992, 41 (RR-17):1-19.
14. SAS Institute: SAS/STAT Users Guide, Version 6, Fourth Edition. Cary: SAS Institute, Inc.; 1992.
15. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
16. Breslow NE, Day N: Statistical Methods in Cancer Research: The Analysis of Case-control Studies, Vol. 1. Lyon: International Agency for Research on Cancer; 1980.
17. Cooper D, CAESAR Coordinating Committee: The CAESAR trial: final results. 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 367].
18. Phillips AN, Lundgren JD, EUROSIDA Study Group: Association of use of additional nucleoside analogues (NA) with mortality in 2410 patients initially treated with zidovudine (ZDV). 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 563].
19. Joannidis JPA, Cappelleri JC, Lau J, et al.: Early or deferred zidovudine therapy in HIV-infected patients without an AIDS defining illness. Ann Intern Merd 1995,122:856-866.
20. Eyseneck HJ: Meta-analysis and its problems. Br Med J 1994, 309:789-792.
21. Feigal DW, Katz MH, Greenspan D, et al.: The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 1991, 5:519-525.
22. Moss AR, Bacchetti P, Osmond D, et al.: Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J 1988, 296:745-750.
23. Cooper DA, Gatell JM, Kroon S, et al.: Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993, 329: 297-303.
24. Concorde Coordinating Committee: Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343:871-881.
25. Lubsen J: Mega-trials: is meta-analysis an alternative? Eur J Pharmacol 1996, 49 (suppl 1):S29-S33.